Please login to the form below
Alzheimer's drug treatment
This page shows the latest Alzheimer's drug treatment news and features for those working in and with pharma, biotech and healthcare.
FDA grants priority review for traditional approval of Biogen and Eisai’s Alzheimer’s drug
The US Food and Drug Administration (FDA) has granted priority review for the traditional approval of Eisai and Biogen's Alzheimer’s treatment, Leqembi (lecanemab-irmb). ... Biogen’s own Alzheimer’s drug, Aduhelm (aducanumab), received a
Latest news
-
Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US
Following a thorough analysis, CMS discovered that although Aduhelm had the potential to help patients with Alzheimer's disease, the drug also had the potential to cause harm. ... Echoing Biogen’s comments, Harry Johns, chief executive officer of the
-
First trial of a vaccine against Alzheimer’s launches
He added “If clinical trials in humans show that the vaccine is safe and effective, this could represent a nontoxic treatment for people with Alzheimer’s, and it could also be ... However, there has been renewed interest across the industry in recent
-
Biogen investigating death linked to Aduhelm
The search for an effective treatment for the most common form of dementia, Alzheimer’s disease, has been long and hard in spite of the huge unmet need of the 55 ... as a treatment for Alzheimer’s, bapineuzumab.
-
Rocky start for Biogen’s Alzheimer’s drug Aduhelm
Controversial Alzheimer’s treatment Aduhelm is struggling to realise its potential, with only 100 patients receiving the therapy so far in the US. ... Embattled Biogen has encountered yet more setbacks in the roll-out of its Alzheimer’s disease
-
FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
Biogen’s aducanumab has been approved by the US Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease, in a landmark moment for the therapy area. ... Investors and industry specialists had been anxiously awaiting the FDA’s
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Subscribe to our email news alerts
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
- Want the most from your Pharmaceutical portfolio?
- Diversity and inclusion in clinical trials: keeping up momentum
- 10 Important Advisor Questions: Placement of Your Product in the Current/Future Treatment Algorithm
- Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia
No results were found
PMHub
Dovetail
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
